Way back in the ’90s, Eli Lilly was going around saying its osteoporosis drug Evista reduced the risk of breast cancer and cardiovascular problems, even though the drug hadn’t been approved for those uses. The company got in trouble for that ($36 million fine, guilty misdemeanor plea), but it turns out Lilly was half right.
The FDA has given the company the go-ahead to promote the drug to reduce the risk of breast cancer in some women, Lilly said today. As part of the deal, though, the company also had to add a black-box warning to the drug’s label, calling out its possible increased risk of blood clots in the veins and fatal strokes in certain women.
No comments:
Post a Comment